NOVO-NORDISK A/S-SPONS ADR (NVO)
US6701002056 - ADR
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (5/16/2024, 8:30:03 AM)
133.09
-1.57 (-1.17%)
Company Profile
Novo Nordisk A/S is a DK-based company operating in Pharmaceuticals industry. Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company Info
NOVO-NORDISK A/S-SPONS ADR
Novo Alle 1
Bagsvaerd 2880
P: 4544448888
CEO: Lars Fruergaard Jorgensen
Employees: 61412
Website: https://www.novonordisk.com/
NVO News
2 hours ago - ChartmillShould Quality Investors Include NYSE:NVO in Their Portfolio?Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for quality investing?
3 hours ago - InvestorPlace7 Pharma Stocks Harnessing AI Brainpower for Big BreakthroughsAI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.
4 hours ago - InvestorPlacePatent Peril: 3 Stocks at Risk From the FTC’s Drug CrusadeThe FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
a day ago - The Motley FoolIf You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have TodayBack then, the company wasn't very well known to U.S. investors. That's absolutely not the case these days.
a day ago - The Motley FoolNovo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy.This company is serious about maintaining its leadership.
2 days ago - The Motley Fool2 Top Pharma Stocks That Just Keep Getting Better and BetterBoth of these businesses are finding traction in a pair of major markets.
NVO Twits
Here you can normally see the latest stock twits on NVO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
